Clinical Research Directory

Inclusion Criteria: * Patients with either: * Histologically confirmed invasive carcinoma or multiple myeloma OR * Clinical diagnosis of carcinoma or multiple myeloma OR * Suspected clinical diagnosis of multiple myeloma * Patients with one of following tumor types and age ranges: * Breast cancer diagnosis at ages 18-45 * Colon cancer diagnosis at ages 18-55 * Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native \[AIAN\] and non-Hispanic Whites \[NHW\] only) * Liver cancer diagnosis at ages 18-55 * Prostate cancer diagnosis at ages 18-55 * Multiple myeloma diagnosis at ages 18-50 * Patients whose tumor specimen was collected or will be collected during one of the following routine procedures: * Surgery to remove cancer OR * Routine biopsy procedures performed to confirm a histologic diagnosis OR * Routine biopsy procedure performed to obtain additional tumor material for routine prognostic or predictive biomarkers OR * Routine procedure to place a vascular access device prior for systemic therapy * Patients who have received no therapy for their cancer other than surgery, irrespective of stage * Collection of specimens from living patients: * Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol * Collection of specimens from deceased patients: * Banked tissue samples and/or banked biologic fluid specimens of deceased patients may be used as long as all samples or specimens are properly de- identified prior to submission * Sites must use the Central Institutional Review Board for the National Cancer Institute (NCI CIRB). Exclusion Criteria: * Patients who do not meet criteria for an early onset malignancy * Prior systemic therapy or radiation therapy for their malignancy * Tumor does not meet quality metrics * Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative * A diagnosis of a synchronous invasive malignancy * Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years